Barely Significant
← all excerpts

Epidemiology and Multidrug Resistance of <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumanni</i> Isolated from Clinical Samples in Ethiopia.

Infect Drug Resist · 2023 · PMC10178297 · PMID 37187480

2
hedged sentences
closest p
boldest claim

The sentences

a decreasing trendno p-value reported
However, a decreasing trend of resistance was observed for tobramycin (61.1% to 25.2%), followed by Tazobactam (84.6% to 63.2%), and Amikacin (31.6% to 26.2%) ( Figure 4 ).

also in 47,180 other papers

an increasing trendno p-value reported
tazobactam (22.2% to 26.7%), Meropenem (20.7% to 38.9%), Cefotaxime (71.4% to 100%), Ciprofloxacin (18.5% to 25.5%), Tobramycin (42.9% to 33.3%), Ceftazidime (30.2% to 16.7%), Ceftriaxone (76.5% to 66.7%), Amikacin (9.4% to 9.2%) showed decrease in resistance pattern ( Figure 3 ). An increasing trend of antimicrobial resistance for A. baumanni was observed in the five years ampicillin (86% to 92%), followed by Amoxicillin-clavulanate (81% to 84.7%), chloramphenicol (76% to 82.3%), and Cefotaxime (66.7% to 82.2%).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.